Advertisement
Screener

MaxCyte, Inc. (MXCT) EBITDA

MaxCyte, Inc. (MXCT) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$9.25M*; Operating income -$10.23M; Depreciation and amortization $978.00K*.
  • 2026-03-31: Basis Reported; EBITDA -$5.14M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$10.15M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$13.08M*; Operating income -$14.15M; Depreciation and amortization $1.07M*.

Complete source-backed ebitda history.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$9.25M*-$10.23M$978.00K*$4.94M-187.48%*$62.00K*-$4.66M*$1.68M$4.25M(m)(m)
2026-03-31Reported-$5.14M(m)(m)(m)-114.15%$72.00K-$8.17M$1.57M$3.86M(m)(m)
2025-12-31Reported-$10.15M(m)(m)(m)-212.12%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$13.08M*-$14.15M$1.07M*$4.60M-284.10%*$300.00K*-$7.46M*$1.60M$5.32M(m)(m)
2025-06-30Reported-$13.13M*-$14.23M$1.10M*$5.82M-225.39%*$584.00K*-$9.85M*$1.52M$6.27M(m)(m)
2025-03-31Reported-$11.2M(m)(m)(m)-195.00%$653.00K-$14.41M$1.50M$5.90M(m)(m)
2024-12-31Reported-$11.84M(m)(m)(m)-195.61%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$12.99M(m)(m)(m)-231.41%$406.00K*-$4.39M*$1.93M$5.32M(m)(m)
2024-06-30Reported-$10.89M(m)(m)(m)-219.27%$294.00K*-$4.83M*$1.49M$5.62M(m)(m)
2024-03-31Reported-$11.16M(m)(m)(m)-199.93%$804.00K-$10.56M$1.40M$6.68M(m)(m)
2023-12-31Reported-$6.99M(m)(m)(m)-147.06%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$12.87M(m)(m)(m)-309.70%$720.00K*-$8.24M*$793.00K$6.26M(m)(m)
2023-06-30Reported-$12.05M(m)(m)(m)-214.28%$507.00K*-$10.11M*$1.38M$5.66M(m)(m)
2023-03-31Reported-$12.22M(m)(m)(m)-246.09%$1.56M-$4.32M$1.00M$6.05M(m)(m)
2022-12-31Reported-$5.83M(m)(m)(m)-75.18%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$6.97M(m)(m)(m)-97.43%$3.48M*-$5.92M*$1.37M$5.33M(m)(m)
2022-06-30Reported-$8.19M(m)(m)(m)-117.32%$6.81M*$918.60K*$1.12M$4.70M(m)(m)
2022-03-31Reported-$3.67M(m)(m)(m)-53.54%$6.00M-$3.69M$1.06M$3.77M(m)(m)
2021-12-31Reported-$4.54M(m)(m)(m)-60.47%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$2.08M(m)(m)(m)-37.03%$1.44M*-$690.45K*$943.80K$2.75M(m)(m)
2021-06-30Reported-$4.09M(m)(m)(m)-97.01%$962.60K*-$4.39M*$784.50K$3.20M(m)(m)
2021-03-31Reported-$6.06M(m)(m)(m)-142.89%$308.50K-$4.64M$693.10K$6.08M(m)(m)
2020-09-30Reported(m)-$2.84M(m)$4.67M(m)$663.40K*-$830.30K*(m)$4.52M(m)(m)
2020-06-30Reported(m)-$2.84M(m)$2.33M(m)(m)(m)(m)$4.09M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$47.56M(m)(m)(m)-226.93%$1.77M-$34.41M$6.22M$20.82M(m)(m)
2024-12-31Reported-$46.88M(m)(m)(m)-211.04%$1.65M-$27.61M$7.10M$22.23M(m)(m)
2023-12-31Reported-$44.13M(m)(m)(m)-226.33%$3.70M-$21.69M$4.74M$23.82M(m)(m)
2022-12-31Reported-$24.66M(m)(m)(m)-85.79%$18.48M-$14.78M$5.10M$19.51M(m)(m)
2021-12-31Reported-$16.76M(m)(m)(m)-77.72%$3.83M-$10.68M$3.65M$15.41M(m)$0.00
2020-12-31Reported-$10.01M(m)(m)(m)-64.78%$2.07M-$8.78M$2.77M$17.73M(m)$0.00
2019-12-31Reported-$11.81M(m)(m)(m)-89.06%$1.27M-$8.80M$2.50M$17.59M(m)$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14